Dabrafenib + Trametinib in Patients w/rare BRAF V600E Mutated Solid Tumor (CDRB436IIC01)

Purpose of this Study

We are doing this study to collect information about how well dabrafenib plus trametinib works in patients who have unresectable (cannot be removed by surgery) or metastatic BRAF V600E mutation positive solid tumors.

Who Can Participate?

Eligibility

Adults ages 18+ who:<ul>
<li>Are diagnosed with unresectable or metastatic BRAF V600E mutation positive solid tumors</li>
<li>Have not received dabrafenib-trametinib previously for your disease or have not received it for more than one year for any other malignancy</li></ul>
For more information about who can join this study, please contact the study team at gi-oncology-cru@dm.duke.edu or 919-668-1861.

What is Involved?

If you choose to join this study, we will collect information related to your cancer and treatment and enter it into a database that we will keep indefinitely. This information will help us better understand how the drug combination works for people who have this rare mutation.

Study Details

Full Title

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors

Principal Investigator

John
Strickler

Protocol Number

PRO00113811

NCT ID

NCT05868629

Phase

IV

Enrollment Status

Open to Enrollment